GC304
/ GeneCradle
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 13, 2025
Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients with Recurrent Pancreatitis
(clinicaltrials.gov)
- P1 | N=7 | Recruiting | Sponsor: GeneCradle Inc | Trial primary completion date: Dec 2025 ➔ Dec 2026
Trial primary completion date • Dyslipidemia • Gene Therapies • Hypertriglyceridemia • Pancreatitis
September 25, 2024
Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis
(clinicaltrials.gov)
- P1 | N=7 | Recruiting | Sponsor: GeneCradle Inc | Not yet recruiting ➔ Recruiting | N=12 ➔ 7
Enrollment change • Enrollment open • Gene therapy • Dyslipidemia • Gene Therapies • Hypertriglyceridemia • Pancreatitis
February 23, 2024
Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis
(clinicaltrials.gov)
- P1 | N=12 | Not yet recruiting | Sponsor: GeneCradle Inc | Initiation date: Dec 2023 ➔ Dec 2024
Gene therapy • Trial initiation date • Dyslipidemia • Gene Therapies • Hypertriglyceridemia • Pancreatitis
May 16, 2023
Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis
(clinicaltrials.gov)
- P1 | N=12 | Not yet recruiting | Sponsor: GeneCradle Inc
Gene therapy • New P1 trial • Dyslipidemia • Gene Therapies • Hypertriglyceridemia • Pancreatitis • LPL
1 to 4
Of
4
Go to page
1